Frankfurt - Delayed Quote EUR
HBM Holdings Limited (6XY.F)
0.9000
+0.0500
+(5.88%)
At close: April 25 at 8:41:26 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
38,100
38,100
89,502
40,659
4,308
Cost of Revenue
4,486
4,486
2,034
130
137
Gross Profit
33,614
33,614
87,468
40,529
4,171
Operating Expense
35,799
35,799
64,801
161,856
144,350
Operating Income
-2,185
-2,185
22,667
-121,327
-140,179
Net Non Operating Interest Income Expense
3,278
3,278
1,752
879
2,093
Pretax Income
3,739
3,739
22,682
-137,020
-137,829
Tax Provision
997
997
-81
248
49
Net Income Common Stockholders
2,778
2,778
22,797
-137,222
-137,777
Diluted NI Available to Com Stockholders
2,778
2,778
22,797
-137,222
-137,777
Basic EPS
0.00
0.00
0.03
-0.19
-0.19
Diluted EPS
0.00
0.00
0.03
-0.19
-0.19
Basic Average Shares
768,246.2950
768,246.2950
733,944.3770
729,435.2070
732,377.3570
Diluted Average Shares
772,456.7020
772,456.7020
742,530.0100
729,435.2070
732,377.3570
Total Expenses
40,285
40,285
66,835
161,986
144,487
Net Income from Continuing & Discontinued Operation
2,778
2,778
22,797
-137,222
-137,777
Normalized Income
1,662.5729
1,662.5729
23,596.4800
-128,138.5800
-137,912.0500
Interest Income
6,783
6,783
5,624
2,866
2,269
Interest Expense
3,505
3,505
3,872
1,987
176
Net Interest Income
3,278
3,278
1,752
879
2,093
EBIT
7,244
7,244
26,554
-135,033
-137,653
EBITDA
10,129
10,129
31,185
-126,998
-130,844
Reconciled Cost of Revenue
4,486
4,486
2,034
130
137
Reconciled Depreciation
2,885
2,885
4,631
8,035
6,809
Net Income from Continuing Operation Net Minority Interest
2,778
2,778
22,797
-137,222
-137,777
Total Unusual Items Excluding Goodwill
1,521
1,521
-1,012
-11,498
185
Total Unusual Items
1,521
1,521
-1,012
-11,498
185
Normalized EBITDA
8,608
8,608
32,197
-115,500
-131,029
Tax Rate for Calcs
0.0003
0.0003
0.0002
0.0002
0.0003
Tax Effect of Unusual Items
405.5729
405.5729
-212.5200
-2,414.5800
49.9500
12/31/2021 - 2/3/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
2QV0.F Chemomab Therapeutics Ltd.
1.0900
+2.83%
PBN.F Alterity Therapeutics Limited
0.0045
+12.50%
FAB.L Fusion Antibodies plc
6.80
-9.09%
TRMED.OL Thor Medical ASA
2.4000
-2.24%
ELIC.ST Elicera Therapeutics AB (publ)
4.3500
+13.73%
FARN.L Faron Pharmaceuticals Oy
202.00
-0.25%
BIOVIC-B.ST Biovica International AB (publ)
0.6980
+9.06%
MEDCL.PA MedinCell S.A.
14.97
+0.13%
VVY.AS Vivoryon Therapeutics N.V.
1.7760
-1.88%
SEOVF Sernova Biotherapeutics Inc
0.1400
-2.10%